Abstract
Myeloproliferative neoplasms (MPNs) are clonal bone marrow (BM) proliferations that most often manifest as increased peripheral blood (PB) counts and/or splenomegaly. Unlike myelodysplastic syndromes, the hemopoiesis in MPN is effective, leading to the increased peripheral counts; unlike the acute leukemias, there is intact maturation of all hematopoietic lineages. The main MPN entities discussed in this chapter are polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The uncommon MPN entities of chronic neutrophilic leukemia and unclassifiable MPN are also discussed. An activating point mutation in the JAK2 gene underlies the pathogenesis of many MPN, including almost all cases of polycythemia vera and about half of essential thrombocythemia and primary myelofibrosis cases. Accurate diagnosis of MPN involves distinguishing these neoplasms from reactive causes of increased PB counts as well as appropriate classification of MPN into specific entities. The diagnosis of MPN requires an integration of clinical features, BM morphology, and genetic tests, in particular JAK2 mutation analysis. Therapeutic approaches, including targeted therapy as pertinent, are also discussed for each entity.
Keywords: Myeloproliferative neoplasm, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic idiopathic myelofibrosis, myeloid metaplasia, chronic neutrophilic leukemia, JAK2
Current Cancer Therapy Reviews
Title: Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Volume: 8 Issue: 1
Author(s): Robert P. Hasserjian
Affiliation:
Keywords: Myeloproliferative neoplasm, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic idiopathic myelofibrosis, myeloid metaplasia, chronic neutrophilic leukemia, JAK2
Abstract: Myeloproliferative neoplasms (MPNs) are clonal bone marrow (BM) proliferations that most often manifest as increased peripheral blood (PB) counts and/or splenomegaly. Unlike myelodysplastic syndromes, the hemopoiesis in MPN is effective, leading to the increased peripheral counts; unlike the acute leukemias, there is intact maturation of all hematopoietic lineages. The main MPN entities discussed in this chapter are polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The uncommon MPN entities of chronic neutrophilic leukemia and unclassifiable MPN are also discussed. An activating point mutation in the JAK2 gene underlies the pathogenesis of many MPN, including almost all cases of polycythemia vera and about half of essential thrombocythemia and primary myelofibrosis cases. Accurate diagnosis of MPN involves distinguishing these neoplasms from reactive causes of increased PB counts as well as appropriate classification of MPN into specific entities. The diagnosis of MPN requires an integration of clinical features, BM morphology, and genetic tests, in particular JAK2 mutation analysis. Therapeutic approaches, including targeted therapy as pertinent, are also discussed for each entity.
Export Options
About this article
Cite this article as:
P. Hasserjian Robert, Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable, Current Cancer Therapy Reviews 2012; 8 (1) . https://dx.doi.org/10.2174/157339412799462495
DOI https://dx.doi.org/10.2174/157339412799462495 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety and Efficacy of Immune Checkpoint Inhibitors in Children and
Young Adults with Haematological Malignancies: Review and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Myelodysplastic Syndromes: Review of Pathophysiology and Current Novel Treatment Approaches
Current Cancer Drug Targets HSP90 Inhibitors: Current Development and Potential in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Pharmacophore Modelling as a Virtual Screening Tool for the Discovery of Small Molecule Protein-protein Interaction Inhibitors
Current Pharmaceutical Design Chromatin Structure and Epigenetics of Tumour Cells: A Review
Cardiovascular & Hematological Disorders-Drug Targets In Vivo Anticancer Activity, Toxicology and Histopathological Studies of the Thiolate Gold(I) Complex [Au(Spyrimidine)(PTA-CH<sub>2</sub>Ph)]Br
Anti-Cancer Agents in Medicinal Chemistry Structure and Ligand-based Design of P-glycoprotein Inhibitors: A Historical Perspective
Current Pharmaceutical Design Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Nanoparticles for Tumor Targeted Therapies and Their Pharmacokinetics
Current Drug Metabolism Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future Prospects
Current Cancer Drug Targets Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Studies on Structures and Functions of Kinases leading to Prostate Cancer and Their Inhibitors
Current Enzyme Inhibition Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities
Current Pharmaceutical Design Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Flavonoids as Anticancer Agents: Structure-Activity Relationship Study
Current Medicinal Chemistry - Anti-Cancer Agents Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism